BioSpace News Archive

Labcorp today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. ( PGDx ), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.

QurAlis Corporation today announced research published in Molecular Biology of the Cell that described the discovery of CELLXPEDITE, a new-generation drug screening platform for ALS.

Vallon Pharmaceuticals, Inc. today announced that the last patient has completed their final visit in the pivotal SEAL intranasal abuse study evaluating ADAIR1.

Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 15, 2022.

Conformis, Inc. (NASDAQ:CFMS) announced today that Brent Alldredge, Chief Legal Officer and Corporate Secretary, has notified the Company that he will be departing the Company on January 16, 2022.

Cassava Sciences, Inc., (NASDAQ: SAVA) a biotechnology company, today announced the launch of a new clinical website, called www.Rethink-ALZ.com. Rethink-ALZ.com is intended to provide access, visibility and information on Cassava Sciences’ Phase 3 safety and efficacy studies of oral simufilam in people with Alzheimer’s disease.

Lion TCR Pte Ltd today announced that it has received Fast Track Designation from United States Food and Drug Administration (U.S. FDA) for LioCyx-M004, autologous T-cells transfected with mRNA encoding Hepatitis B surface antigen (HBsAg) specific TCR, for the treatment of HBV-related hepatocellular carcinoma (HBV-related HCC).

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has acquired 100% of Kestrel Labs, Inc.

MRP.io (“MRP”) announced today that it has signed an exclusive agreement with LUVO Medical, headquartered in Ontario, Canada, for the sale and distribution of four LUVO products in the United States.

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Merck’s molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing.